AAAbdulmajeed Alsuwaylihi

Abdulmajeed Alsuwaylihi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abdulmajeed Alsuwaylihi has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effects of the Sequence of Empiric Beta-Lactam and Vancomycin Administration on Clinical Outcomes in Patients with Bloodstream Infection: A Systematic Review

    by Abdulmajeed Alsuwaylihi, Abdulmajeed M. Alshehri, Majed S. Al Yami

    Background/Objectives: Beta-lactam antibiotics (BLAs) and vancomycin have remained the cornerstones of therapy for serious bacterial infections, especially bloodstream infections (BSIs). The clinical impact of administering BLAs before vancomycin on outcomes remains unclear and poorly synthesized. Therefore, this systematic review aims to synthesize the available evidence on the impact of the relative timing of BLA administration to vancomycin initiation on important clinical outcomes in patients with BSIs. Methods: A comprehensive search was performed to retrieve clinical studies that evaluated the impact of the sequence of BLA and vancomycin administration on clinical outcomes. Beta-lactam–first group (BLF) included patients who received a BLA before vancomycin, while vancomycin–first group (VF) included patients who received vancomycin prior to BLAs. The systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Results: A total of three retrospective observational studies were included, with a sample size of 29,005 patients, with 24,356 patients in the BLF and 4649 patients in the VF. One study reported that prioritizing BLAs over vancomycin resulted in a 52% reduction in 7-day mortality (adjusted OR, 0.48; 95% CI, 0.33–0.69) and a 55% reduction in 48 h mortality (adjusted OR: 0.45; 95% Cl, 0.24–0.83). Similarly, another study found the BLF strategy was associated with a modest reduction in in-hospital mortality (adjusted OR: 0.89; 95% CI: 0.80–0.99). However, no difference was found in the most recent small, single-institution study that included patients with BSIs. Conclusions: The evidence suggests a potential survival benefit for the BLF strategy over VF in patients with suspected or confirmed BSIs. Larger prospective studies are required to confirm the findings.


  • Open Access

    Comparison of Safety and Effectiveness Between Direct Oral Anticoagulants and Vitamin K Antagonists in Dementia Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis

    by Abdulmajeed M. Alshehri, Lama Alfehaid, Solaiman Alhawas, Abdulmajeed Alsuwaylihi, Abdulaziz Alarifi, Majed S. Al Yami

    Background/Objectives: The question of whether the benefits of anticoagulation outweigh the risks of bleeding in patients with dementia and atrial fibrillation (AF) remains unresolved. This study aimed to evaluate the effectiveness of oral anticoagulation (OAC) and to compare the safety and effectiveness of direct oral anticoagulants (DOACs) with vitamin K antagonists (VKAs) within this at-risk population. Methods: This meta-analysis was conducted following the PRISMA guidelines and was registered in PROSPERO. Data were extracted from MEDLINE, Web of Science, and Cochrane Library. The Newcastle–Ottawa Scale was used to assess the risk of bias. The outcomes were analyzed using the Comprehensive Meta-Analysis software, with odds ratios (ORs) and 95% confidence intervals (CIs) calculated for dichotomous variables. Results: Eight retrospective studies were included, with sample sizes of up to 40,350 participants. The primary outcome was mortality incidence, while secondary outcomes included ischemic stroke, major bleeding, and intracranial hemorrhage (ICH). DOACs significantly reduced ICH events compared to VKAs (OR 0.38, 95% CI 0.17–0.84; I2 = 87.3%) but showed no significant difference in major bleeding (OR 0.48, 95% CI 0.22–1.03; I2 = 88%). Mortality and ischemic stroke rates were similar between the DOAC and VKA groups. OAC use reduced mortality by 29% compared to no OAC (OR 0.71, 95% CI 0.57–0.88; I2 = 81.3%) but increased major bleeding risk (OR 1.19, 95% CI 1.08–1.3; I2 = 0%). Conclusions: DOACs offer a safer profile regarding ICH in dementia patients with AF compared to VKAs, with no significant differences in mortality or ischemic stroke rates. This study highlights the need for careful anticoagulant selection in this vulnerable population.